Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag veklury

Gilead tags Merck for first-line triple negative breast cancer trial

pharmaphorum

OCTOBER 29, 2021

COVID-19 therapy Veklury (remdesivir) continued to lead the charge at Gilead with a massive $1.9 billion was a healthy 13% rise, taking Veklury out of the equation would have resulted in a 3% decline. The post Gilead tags Merck for first-line triple negative breast cancer trial appeared first on. billion for the full year.

Trials

Trials Sales FDA Approval Production

Targeting a human protein may stop Ebola virus in its tracks

The Pharma Data

MARCH 23, 2022

Back in 2018, researchers tested a broad-spectrum antiviral candidate called remdesivir/VEKLURY, which acts as a nucleotide decoy to get incorporated into the viral RNA genome and stop viral polymerase. In fact, antiviral therapies designed to treat viruses such as hepatitis C (Sofosbuvir/SOVALDI) work by blocking viral polymerase.

Protein

Protein Genome Genomics Research

Gilead tags Merck for first-line triple negative breast cancer trial

Targeting a human protein may stop Ebola virus in its tracks

Stay Connected